Please ensure Javascript is enabled for purposes of website accessibility

1 Feel-Good Healthcare Stock That Could Turn Your Tax Return Into Riches

By Patrick Bafuma - Apr 22, 2021 at 7:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

TransMedics is looking to disrupt an entire industry and help thousands of transplant patients in the U.S. in the process.

It may surprise you to learn that many donated organs never get used. Less than a third of donated hearts and less than a quarter of donated lungs end up making their way to a recipient. But a company called TransMedics (TMDX 2.72%) hopes to change that, looking to disrupt the way organs are transplanted by transforming the way donated organs are procured and stored for delivery. 

Improving the process

Currently in the U.S., after organs are harvested from a donor, they are stored in cold temperatures for transport. During transport, which can often take several hours, organs can deteriorate until they are no longer usable. But with TransMedics' Organ Care System (OCS), each organ can be continuously monitored and optimized for a successful donation during transport. With the TransMedics OCS, post-transplant complication rates are significantly decreased for heart and lung transplants, from a range of 30% to 35% to just 10%-14%.

Doctor's hands holding a representation of a heart

Image source: Getty Images. 

Not only that, but the percentage of hearts that can be utilized for transplantation increases from 32% to 81% with OCS, and the percentage of lungs that can be utilized for transplant increases from 23% to 87%. For liver transplants, the numbers are similar, with a 98% utilization rate and a 43% reduction of severe post-transplant complications. All in all, that is a lot of patients with hopes and dreams answered.

TransMedics sells a separate single-use OCS for each organ; so far, the FDA has only approved the system for lungs, but there is hope for heart and liver OCS approval in 2021. The company also sells the reagents needed to run the OCS system. With gross margins of about 63%, this could be a profitable option for healthcare investors.

Future drivers of growth

COVID-19 put a damper on transplants last year, with a 25% decrease in organ recovery from February to April of 2020. Despite this, for the full year 2020 (ending Dec. 31), TransMedics reported net revenue of $25.6 million, representing 9% growth over 2019. Likewise, even with what was likely a decrease in organ procurement due to the pandemic, 4Q 2020 net revenue was up 26% year over year at $7.6 million.

The company started 2020 with one active region utilizing OCS (the Chicago area) and closed out the year with four, adding New England, Atlanta, and Dallas. Management plans to continue increasing regional coverage in the U.S., aiming for at least 10 regions by the end of 2021.  I think we can continue to expect significant revenue growth -- likely north of 26% going forward.

A nudge from Uncle Sam

In November, the Centers for Medicare & Medicaid Services (CMS) finalized a rule that was designed to increase the supply of organs available for transplant. With over 113,000 Americans on a transplant list, CMS acted by requiring organizations responsible for organ procurement to be transparent in performance reporting -- and requiring these organizations to compete on their ability to successfully facilitate transplants.

This opens the door for TransMedics to push to become a national provider for all OCS-related organ retrieval and clinical management activities for transplant centers in the U.S. In this scenario, TransMedics would not only sell the OCS and its consumables for transport, but would also be the transporter and the medical team providing surgical retrieval of the organs. This is a huge wild card that may not necessarily materialize, but it does provide another potential avenue of growth for the company -- though the size of the addressable market remains unclear. Management seems incredibly excited about the possibilities, though, mentioning the issue at least 10 times on its most recent earnings call.

How big are these markets?

Annually in the U.S., there are about 2,000 lung transplants, 2,000 heart transplants, and 8,000 liver transplants. If each OCS costs roughly $50,000 per patient, for all three indications, that is a $600 million total addressable market. And that's just for the consumables, without even counting the transport or organ procurement reimbursement that management is so excited about. Given the company's current market cap of roughly $800 million, that leaves a lot of room for stock appreciation.

A feel-good story

With a large total addressable market and potential to expand its reach into organ procurement and transportation, there is a lot to like about TransMedics. I can easily envision accelerated growth due to increased geographic expansion, the easing of the COVID-19 pandemic, and a greater number of transplants happening thanks to the OCS. Healthcare investors may not only reap financial rewards from this holding, they can also feel good knowing the company is helping to save lives.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TransMedics Group, Inc. Stock Quote
TransMedics Group, Inc.
TMDX
$32.15 (2.72%) $0.85

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.